Gaps remain in market for novel osteoporosis treatments

A new report from industry analyst GlobalData highlights the low rate of diagnosis and treatment for osteoporosis, resulting in a high burden on both patients and society.

The document, ‘ Global Drug Forecast and Market Analysis to 2027’, shows that the overall osteoporosis market is expected to grow at a compound annual growth rate of 3.2%, reaching peak sales for the sector of just over $10 billion by 2027.

However, poor diagnosis rates, negative perceptions of drug side effects and low compliance rates will likely impede growth in the next decade.